Ignite Creation Date:
2025-12-24 @ 2:24 PM
Ignite Modification Date:
2026-02-20 @ 12:45 PM
Study NCT ID:
NCT00611559
Status:
COMPLETED
Last Update Posted:
2018-06-06
First Post:
2008-01-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011051', 'term': 'Poliomyelitis'}, {'id': 'D013742', 'term': 'Tetanus'}, {'id': 'D004165', 'term': 'Diphtheria'}, {'id': 'D006509', 'term': 'Hepatitis B'}], 'ancestors': [{'id': 'D009187', 'term': 'Myelitis'}, {'id': 'D002494', 'term': 'Central Nervous System Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D004769', 'term': 'Enterovirus Infections'}, {'id': 'D010850', 'term': 'Picornaviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000090862', 'term': 'Neuroinflammatory Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D003015', 'term': 'Clostridium Infections'}, {'id': 'D016908', 'term': 'Gram-Positive Bacterial Infections'}, {'id': 'D001424', 'term': 'Bacterial Infections'}, {'id': 'D001423', 'term': 'Bacterial Infections and Mycoses'}, {'id': 'D003354', 'term': 'Corynebacterium Infections'}, {'id': 'D000193', 'term': 'Actinomycetales Infections'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D018347', 'term': 'Hepadnaviridae Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D006525', 'term': 'Hepatitis, Viral, Human'}, {'id': 'D006505', 'term': 'Hepatitis'}, {'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C472675', 'term': 'PEDIARIX'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'phone': '866-435-7343', 'title': 'GSK Response Center', 'organization': 'GlaxoSmithKline'}, 'certainAgreement': {'otherDetails': 'GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa', 'otherNumAtRisk': 111, 'deathsNumAtRisk': 111, 'otherNumAffected': 59, 'seriousNumAtRisk': 111, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa', 'otherNumAtRisk': 115, 'deathsNumAtRisk': 115, 'otherNumAffected': 62, 'seriousNumAtRisk': 115, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta', 'otherNumAtRisk': 57, 'deathsNumAtRisk': 57, 'otherNumAffected': 26, 'seriousNumAtRisk': 57, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 35}, {'groupId': 'EG001', 'numAtRisk': 115, 'numAffected': 36}, {'groupId': 'EG002', 'numAtRisk': 57, 'numAffected': 14}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Redness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 54}, {'groupId': 'EG001', 'numAtRisk': 115, 'numAffected': 54}, {'groupId': 'EG002', 'numAtRisk': 57, 'numAffected': 22}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 39}, {'groupId': 'EG001', 'numAtRisk': 115, 'numAffected': 45}, {'groupId': 'EG002', 'numAtRisk': 57, 'numAffected': 19}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Drowsiness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 115, 'numAffected': 18}, {'groupId': 'EG002', 'numAtRisk': 57, 'numAffected': 8}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Fever', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 18}, {'groupId': 'EG001', 'numAtRisk': 115, 'numAffected': 15}, {'groupId': 'EG002', 'numAtRisk': 57, 'numAffected': 6}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Irritability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 115, 'numAffected': 21}, {'groupId': 'EG002', 'numAtRisk': 57, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Loss of appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 111, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 115, 'numAffected': 14}, {'groupId': 'EG002', 'numAtRisk': 57, 'numAffected': 5}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '92', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'categories': [{'measurements': [{'value': '88', 'groupId': 'OG000'}, {'value': '92', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'One month after the booster dose', 'description': 'Anti-HB antibodies cut-off value assessed was ≥ 10 milli-international units per milliliter (mIU/mL)', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'PRIMARY', 'title': 'Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '79', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'categories': [{'measurements': [{'value': '74', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'One month after the booster dose', 'description': 'Anti-PRP antibodies cut-off value assessed was ≥ 0.15 microgram per milliliter (µg/mL)', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'PRIMARY', 'title': 'Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off One Month After the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'OG000'}, {'value': '79', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Anti-diphtheria', 'categories': [{'measurements': [{'value': '76', 'groupId': 'OG000'}, {'value': '76', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}]}]}, {'title': 'Anti-tetanus', 'categories': [{'measurements': [{'value': '76', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'One month after the booster dose', 'description': 'Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 international units per milliliter (IU/mL)', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'PRIMARY', 'title': 'Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off One Month After the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '52', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Anti-poliovirus type 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '55', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}]}, {'title': 'Anti-poliovirus type 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '55', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}]}]}, {'title': 'Anti-poliovirus type 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '52', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '55', 'groupId': 'OG000'}, {'value': '52', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'One month after the booster dose', 'description': 'Anti-poliovirus antibodies cut-off value assessed was ≥ 8 effective dose 50 (ED50)', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'PRIMARY', 'title': 'Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration One Month After the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '89', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Anti-PT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '84', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '65.5', 'groupId': 'OG000', 'lowerLimit': '49.8', 'upperLimit': '86.3'}, {'value': '84.2', 'groupId': 'OG001', 'lowerLimit': '61.5', 'upperLimit': '115.4'}, {'value': '43.9', 'groupId': 'OG002', 'lowerLimit': '22.4', 'upperLimit': '85.8'}]}]}, {'title': 'Anti-FHA', 'denoms': [{'units': 'Participants', 'counts': [{'value': '86', 'groupId': 'OG000'}, {'value': '69', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '476.6', 'groupId': 'OG000', 'lowerLimit': '369.7', 'upperLimit': '614.4'}, {'value': '428.3', 'groupId': 'OG001', 'lowerLimit': '311.2', 'upperLimit': '589.5'}, {'value': '221.1', 'groupId': 'OG002', 'lowerLimit': '120.3', 'upperLimit': '406.6'}]}]}, {'title': 'Anti-PRN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '89', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '418.1', 'groupId': 'OG000', 'lowerLimit': '303.2', 'upperLimit': '576.6'}, {'value': '384.1', 'groupId': 'OG001', 'lowerLimit': '271.3', 'upperLimit': '544.0'}, {'value': '251.6', 'groupId': 'OG002', 'lowerLimit': '143.9', 'upperLimit': '439.7'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'One month after the booster dose', 'description': 'Concentration of anti-PT, ant-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per millilitre (EL.U/mL)', 'unitOfMeasure': 'EL.U/mL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off Before and One Month After the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': '≥ 10 mIU/mL Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '87', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}, {'value': '44', 'groupId': 'OG002'}]}]}, {'title': '≥ 100 mIU/mL Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '57', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '35', 'groupId': 'OG002'}]}]}, {'title': '≥ 100 mIU/mL Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '92', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '85', 'groupId': 'OG000'}, {'value': '87', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Anti-HB antibodies cut-off value assessed were ≥ 10 mIU/mL and ≥ 100 mIU/mL\n\nNumber of subjects with cut-off ≥ 10 mIU/mL one month after the booster dose was already presented in the primary outcomes', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Anti-HB Antibodies Concentration', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '93', 'groupId': 'OG000'}, {'value': '93', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '163.5', 'groupId': 'OG000', 'lowerLimit': '114.3', 'upperLimit': '233.7'}, {'value': '161.2', 'groupId': 'OG001', 'lowerLimit': '111.5', 'upperLimit': '232.9'}, {'value': '196.9', 'groupId': 'OG002', 'lowerLimit': '124.2', 'upperLimit': '312.2'}]}]}, {'title': 'Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '91', 'groupId': 'OG000'}, {'value': '92', 'groupId': 'OG001'}, {'value': '48', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4668.0', 'groupId': 'OG000', 'lowerLimit': '2861.4', 'upperLimit': '7615.3'}, {'value': '4962.3', 'groupId': 'OG001', 'lowerLimit': '3289.7', 'upperLimit': '7485.4'}, {'value': '3867.8', 'groupId': 'OG002', 'lowerLimit': '1751.4', 'upperLimit': '8541.5'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Concentration of anti-HB antibodies given as GMC in mIU/mL', 'unitOfMeasure': 'mIU/mL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Number of Subjects With Anti-PRP Antibodies Concentrations Above the Cut-off Before and One Month After the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '79', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': '≥ 0.15 µg/mL Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '72', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '55', 'groupId': 'OG000'}, {'value': '55', 'groupId': 'OG001'}, {'value': '23', 'groupId': 'OG002'}]}]}, {'title': '≥ 1.0 µg/mL Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '72', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '12', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}]}, {'title': '≥ 1.0 µg/mL Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '79', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '69', 'groupId': 'OG000'}, {'value': '74', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Anti-PRP antibodies cut-off value assessed were ≥ 0.15 µg/mL and ≥ 1.0 µg/mL\n\nNumber of subjects with cut-off ≥ 0.15 µg/mL one month after the booster dose was already presented in the primary outcomes', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Anti-PRP Antibodies Concentration', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '79', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '72', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.3', 'groupId': 'OG000', 'lowerLimit': '0.2', 'upperLimit': '0.4'}, {'value': '0.4', 'groupId': 'OG001', 'lowerLimit': '0.3', 'upperLimit': '0.5'}, {'value': '0.2', 'groupId': 'OG002', 'lowerLimit': '0.1', 'upperLimit': '0.4'}]}]}, {'title': 'Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '76', 'groupId': 'OG000'}, {'value': '79', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '25.3', 'groupId': 'OG000', 'lowerLimit': '16.0', 'upperLimit': '40.0'}, {'value': '34.7', 'groupId': 'OG001', 'lowerLimit': '22.9', 'upperLimit': '52.7'}, {'value': '0.4', 'groupId': 'OG002', 'lowerLimit': '0.2', 'upperLimit': '0.7'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Concentration of anti-PRP antibodies given as GMC in µg/mL', 'unitOfMeasure': 'µg/mL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off Before the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '72', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Anti-diphtheria', 'categories': [{'measurements': [{'value': '45', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '23', 'groupId': 'OG002'}]}]}, {'title': 'Anti-tetanus', 'categories': [{'measurements': [{'value': '69', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Before the booster dose administration (at baseline)', 'description': 'Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 IU/mL', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Anti-diphtheria and Anti-tetanus Antibodies Concentration', 'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'OG000'}, {'value': '79', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Anti-diphtheria Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'OG000'}, {'value': '72', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.2', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '0.2'}, {'value': '0.2', 'groupId': 'OG001', 'lowerLimit': '0.1', 'upperLimit': '0.3'}, {'value': '0.1', 'groupId': 'OG002', 'lowerLimit': '0.1', 'upperLimit': '0.2'}]}]}, {'title': 'Anti-diphtheria Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'OG000'}, {'value': '79', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2.7', 'groupId': 'OG000', 'lowerLimit': '1.9', 'upperLimit': '3.7'}, {'value': '3.4', 'groupId': 'OG001', 'lowerLimit': '2.5', 'upperLimit': '4.5'}, {'value': '2.2', 'groupId': 'OG002', 'lowerLimit': '1.4', 'upperLimit': '3.5'}]}]}, {'title': 'Anti-tetanus Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '72', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.5', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '0.6'}, {'value': '0.5', 'groupId': 'OG001', 'lowerLimit': '0.3', 'upperLimit': '0.7'}, {'value': '0.3', 'groupId': 'OG002', 'lowerLimit': '0.2', 'upperLimit': '0.4'}]}]}, {'title': 'Anti-tetanus Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'OG000'}, {'value': '79', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4.9', 'groupId': 'OG000', 'lowerLimit': '3.6', 'upperLimit': '6.7'}, {'value': '6.9', 'groupId': 'OG001', 'lowerLimit': '5.3', 'upperLimit': '9.0'}, {'value': '4.5', 'groupId': 'OG002', 'lowerLimit': '2.8', 'upperLimit': '7.4'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Concentration of anti-diphtheria and anti-tetanus antibodies given as GMC in IU/mL', 'unitOfMeasure': 'IU/mL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentration Above the Cut-off Before and One Month After the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '89', 'groupId': 'OG000'}, {'value': '84', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Anti-PT Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '83', 'groupId': 'OG000'}, {'value': '84', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '45', 'groupId': 'OG000'}, {'value': '43', 'groupId': 'OG001'}, {'value': '26', 'groupId': 'OG002'}]}]}, {'title': 'Anti-PT Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '84', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '79', 'groupId': 'OG000'}, {'value': '66', 'groupId': 'OG001'}, {'value': '25', 'groupId': 'OG002'}]}]}, {'title': 'Anti-FHA Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '85', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '77', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}]}]}, {'title': 'Anti-FHA Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '83', 'groupId': 'OG000'}, {'value': '69', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '86', 'groupId': 'OG000'}, {'value': '69', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}]}]}, {'title': 'Anti-PRN Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '85', 'groupId': 'OG000'}, {'value': '84', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '75', 'groupId': 'OG000'}, {'value': '67', 'groupId': 'OG001'}, {'value': '35', 'groupId': 'OG002'}]}]}, {'title': 'Anti-PRN Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '89', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '88', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Anti-PT, anti-FHA and anti-PRN antibodies cut-off value assessed were ≥ 5 EL.U/mL', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Anti-PT, Anti-FHA, and Anti-PRN Antibodies Concentration Before the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '85', 'groupId': 'OG000'}, {'value': '84', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Anti-PT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '83', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6.6', 'groupId': 'OG000', 'lowerLimit': '5.2', 'upperLimit': '8.4'}, {'value': '6.2', 'groupId': 'OG001', 'lowerLimit': '5.0', 'upperLimit': '7.8'}, {'value': '7.1', 'groupId': 'OG002', 'lowerLimit': '5.3', 'upperLimit': '9.4'}]}]}, {'title': 'Anti-FHA', 'denoms': [{'units': 'Participants', 'counts': [{'value': '85', 'groupId': 'OG000'}, {'value': '77', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '24.5', 'groupId': 'OG000', 'lowerLimit': '18.4', 'upperLimit': '32.6'}, {'value': '22.1', 'groupId': 'OG001', 'lowerLimit': '16.3', 'upperLimit': '30.0'}, {'value': '23.8', 'groupId': 'OG002', 'lowerLimit': '17.3', 'upperLimit': '32.6'}]}]}, {'title': 'Anti-PRN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '85', 'groupId': 'OG000'}, {'value': '84', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '17.5', 'groupId': 'OG000', 'lowerLimit': '13.4', 'upperLimit': '23.0'}, {'value': '13.7', 'groupId': 'OG001', 'lowerLimit': '10.3', 'upperLimit': '18.1'}, {'value': '15.0', 'groupId': 'OG002', 'lowerLimit': '10.3', 'upperLimit': '21.9'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Before the booster dose administration (at baseline)', 'description': 'Concentration of anti-PT, anti-FHA and anti-PRN antibodies given as GMC in EL.U/mL', 'unitOfMeasure': 'EL.U/mL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off Before the Booster Dose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Anti-poliovirus type 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '26', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '46', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}]}]}, {'title': 'Anti-poliovirus type 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '46', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '26', 'groupId': 'OG002'}]}]}, {'title': 'Anti-poliovirus type 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '47', 'groupId': 'OG000'}, {'value': '48', 'groupId': 'OG001'}, {'value': '23', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Before the booster dose', 'description': 'Anti-poliovirus antibodies cut-off value assessed was ≥ 8 ED50', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Anti-poliovirus Antibodies Titer', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Anti-poliovirus type 1 Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '26', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '106.5', 'groupId': 'OG000', 'lowerLimit': '67.9', 'upperLimit': '167.0'}, {'value': '120.4', 'groupId': 'OG001', 'lowerLimit': '76.9', 'upperLimit': '188.4'}, {'value': '85.9', 'groupId': 'OG002', 'lowerLimit': '47.1', 'upperLimit': '156.5'}]}]}, {'title': 'Anti-poliovirus type 1 Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1237.1', 'groupId': 'OG000', 'lowerLimit': '940.7', 'upperLimit': '1626.9'}, {'value': '1939.8', 'groupId': 'OG001', 'lowerLimit': '1465.1', 'upperLimit': '2568.2'}, {'value': '979.5', 'groupId': 'OG002', 'lowerLimit': '539.4', 'upperLimit': '1778.8'}]}]}, {'title': 'Anti-poliovirus type 2 Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '144.4', 'groupId': 'OG000', 'lowerLimit': '96.9', 'upperLimit': '215.2'}, {'value': '102.5', 'groupId': 'OG001', 'lowerLimit': '68.2', 'upperLimit': '154.2'}, {'value': '95.3', 'groupId': 'OG002', 'lowerLimit': '56.3', 'upperLimit': '161.1'}]}]}, {'title': 'Anti-poliovirus type 2 Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '55', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '31', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1412.0', 'groupId': 'OG000', 'lowerLimit': '1096.4', 'upperLimit': '1818.5'}, {'value': '1900.6', 'groupId': 'OG001', 'lowerLimit': '1399.7', 'upperLimit': '2580.7'}, {'value': '916.3', 'groupId': 'OG002', 'lowerLimit': '498.1', 'upperLimit': '1685.5'}]}]}, {'title': 'Anti-poliovirus type 3 Pre', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '98.7', 'groupId': 'OG000', 'lowerLimit': '68.0', 'upperLimit': '143.2'}, {'value': '68.9', 'groupId': 'OG001', 'lowerLimit': '47.0', 'upperLimit': '101.1'}, {'value': '77.5', 'groupId': 'OG002', 'lowerLimit': '41.9', 'upperLimit': '143.4'}]}]}, {'title': 'Anti-poliovirus type 3 Post', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '51', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1485.9', 'groupId': 'OG000', 'lowerLimit': '1041.4', 'upperLimit': '2120.3'}, {'value': '1828.7', 'groupId': 'OG001', 'lowerLimit': '1303.8', 'upperLimit': '2565.1'}, {'value': '605.6', 'groupId': 'OG002', 'lowerLimit': '264.0', 'upperLimit': '1389.1'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Concentration of anti-poliovirus antibodies given as geometric mean titers (GMT)', 'unitOfMeasure': 'titer', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results'}, {'type': 'SECONDARY', 'title': 'Number of Subjects Reporting Solicited Symptoms', 'denoms': [{'units': 'Participants', 'counts': [{'value': '111', 'groupId': 'OG000'}, {'value': '115', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'title': 'Pain', 'categories': [{'measurements': [{'value': '35', 'groupId': 'OG000'}, {'value': '36', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}]}]}, {'title': 'Redness', 'categories': [{'measurements': [{'value': '54', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}]}]}, {'title': 'Swelling', 'categories': [{'measurements': [{'value': '39', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}]}, {'title': 'Drowsiness', 'categories': [{'measurements': [{'value': '21', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}]}]}, {'title': 'Fever', 'categories': [{'measurements': [{'value': '18', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}]}, {'title': 'Irritability', 'categories': [{'measurements': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}]}]}, {'title': 'Loss of appetite', 'categories': [{'measurements': [{'value': '22', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Within the 4-day (Day 0-3) post-vaccination period', 'description': 'Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of Subjects Reporting Unsolicited Adverse Events (AE)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '111', 'groupId': 'OG000'}, {'value': '115', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Within the 31-day (Day 0-30) post-vaccination period', 'description': 'An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of Subjects Reporting Serious Adverse Events (SAE)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '111', 'groupId': 'OG000'}, {'value': '115', 'groupId': 'OG001'}, {'value': '57', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'OG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'OG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Up to one month after the booster dose administration', 'description': 'An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above', 'unitOfMeasure': 'subjects', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'FG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'FG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '111'}, {'groupId': 'FG001', 'numSubjects': '115'}, {'groupId': 'FG002', 'numSubjects': '57'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '110'}, {'groupId': 'FG001', 'numSubjects': '114'}, {'groupId': 'FG002', 'numSubjects': '56'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '111', 'groupId': 'BG000'}, {'value': '115', 'groupId': 'BG001'}, {'value': '57', 'groupId': 'BG002'}, {'value': '283', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'Infanrix Hexa Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix hexa'}, {'id': 'BG001', 'title': 'Infanrix Hexa Preservative-containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix hexa'}, {'id': 'BG002', 'title': 'Infanrix Penta Preservative-free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix penta'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '21.2', 'spread': '1.61', 'groupId': 'BG000'}, {'value': '21.3', 'spread': '1.57', 'groupId': 'BG001'}, {'value': '21.2', 'spread': '1.62', 'groupId': 'BG002'}, {'value': '21.2', 'spread': '1.59', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'months', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '56', 'groupId': 'BG000'}, {'value': '46', 'groupId': 'BG001'}, {'value': '35', 'groupId': 'BG002'}, {'value': '137', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '55', 'groupId': 'BG000'}, {'value': '69', 'groupId': 'BG001'}, {'value': '22', 'groupId': 'BG002'}, {'value': '146', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'White - Caucasian/European Heritage', 'categories': [{'measurements': [{'value': '111', 'groupId': 'BG000'}, {'value': '115', 'groupId': 'BG001'}, {'value': '57', 'groupId': 'BG002'}, {'value': '283', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 283}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-02-14'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-05', 'completionDateStruct': {'date': '2008-06-25', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-04-27', 'studyFirstSubmitDate': '2008-01-29', 'resultsFirstSubmitDate': '2009-06-22', 'studyFirstSubmitQcDate': '2008-01-29', 'lastUpdatePostDateStruct': {'date': '2018-06-06', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2009-06-22', 'studyFirstPostDateStruct': {'date': '2008-02-11', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2009-08-10', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-06-25', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off One Month After the Booster Dose', 'timeFrame': 'One month after the booster dose', 'description': 'Anti-HB antibodies cut-off value assessed was ≥ 10 milli-international units per milliliter (mIU/mL)'}, {'measure': 'Number of Subjects With Anti-polyribosyl-ribitol-phosphate (PRP) Antibodies Concentrations Above the Cut-off One Month After the Booster Dose', 'timeFrame': 'One month after the booster dose', 'description': 'Anti-PRP antibodies cut-off value assessed was ≥ 0.15 microgram per milliliter (µg/mL)'}, {'measure': 'Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off One Month After the Booster Dose', 'timeFrame': 'One month after the booster dose', 'description': 'Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 international units per milliliter (IU/mL)'}, {'measure': 'Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off One Month After the Booster Dose', 'timeFrame': 'One month after the booster dose', 'description': 'Anti-poliovirus antibodies cut-off value assessed was ≥ 8 effective dose 50 (ED50)'}, {'measure': 'Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration One Month After the Booster Dose', 'timeFrame': 'One month after the booster dose', 'description': 'Concentration of anti-PT, ant-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per millilitre (EL.U/mL)'}], 'secondaryOutcomes': [{'measure': 'Number of Subjects With Anti-hepatitis B (HB) Antibody Concentrations Above the Cut-off Before and One Month After the Booster Dose', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Anti-HB antibodies cut-off value assessed were ≥ 10 mIU/mL and ≥ 100 mIU/mL\n\nNumber of subjects with cut-off ≥ 10 mIU/mL one month after the booster dose was already presented in the primary outcomes'}, {'measure': 'Anti-HB Antibodies Concentration', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Concentration of anti-HB antibodies given as GMC in mIU/mL'}, {'measure': 'Number of Subjects With Anti-PRP Antibodies Concentrations Above the Cut-off Before and One Month After the Booster Dose', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Anti-PRP antibodies cut-off value assessed were ≥ 0.15 µg/mL and ≥ 1.0 µg/mL\n\nNumber of subjects with cut-off ≥ 0.15 µg/mL one month after the booster dose was already presented in the primary outcomes'}, {'measure': 'Anti-PRP Antibodies Concentration', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Concentration of anti-PRP antibodies given as GMC in µg/mL'}, {'measure': 'Number of Subjects With Anti-diphtheria and Anti-tetanus Antibodies Concentration Above the Cut-off Before the Booster Dose', 'timeFrame': 'Before the booster dose administration (at baseline)', 'description': 'Anti-diphtheria and anti-tetanus antibodies cut-off value assessed was ≥ 0.1 IU/mL'}, {'measure': 'Anti-diphtheria and Anti-tetanus Antibodies Concentration', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Concentration of anti-diphtheria and anti-tetanus antibodies given as GMC in IU/mL'}, {'measure': 'Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentration Above the Cut-off Before and One Month After the Booster Dose', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Anti-PT, anti-FHA and anti-PRN antibodies cut-off value assessed were ≥ 5 EL.U/mL'}, {'measure': 'Anti-PT, Anti-FHA, and Anti-PRN Antibodies Concentration Before the Booster Dose', 'timeFrame': 'Before the booster dose administration (at baseline)', 'description': 'Concentration of anti-PT, anti-FHA and anti-PRN antibodies given as GMC in EL.U/mL'}, {'measure': 'Number of Subjects With Anti-poliovirus Antibodies Concentration Above the Cut-off Before the Booster Dose', 'timeFrame': 'Before the booster dose', 'description': 'Anti-poliovirus antibodies cut-off value assessed was ≥ 8 ED50'}, {'measure': 'Anti-poliovirus Antibodies Titer', 'timeFrame': 'Before (Pre) and one month after (Post) the booster dose', 'description': 'Concentration of anti-poliovirus antibodies given as geometric mean titers (GMT)'}, {'measure': 'Number of Subjects Reporting Solicited Symptoms', 'timeFrame': 'Within the 4-day (Day 0-3) post-vaccination period', 'description': 'Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite'}, {'measure': 'Number of Subjects Reporting Unsolicited Adverse Events (AE)', 'timeFrame': 'Within the 31-day (Day 0-30) post-vaccination period', 'description': 'An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.'}, {'measure': 'Number of Subjects Reporting Serious Adverse Events (SAE)', 'timeFrame': 'Up to one month after the booster dose administration', 'description': 'An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above'}]}, 'conditionsModule': {'keywords': ['Infanrix hexa', 'combined vaccine'], 'conditions': ['Poliomyelitis', 'Acellular Pertussis', 'Tetanus', 'Diphtheria', 'Hepatitis B']}, 'referencesModule': {'availIpds': [{'id': '110478', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Annotated Case Report Form', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}, {'id': '110478', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Statistical Analysis Plan', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}, {'id': '110478', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Dataset Specification', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}, {'id': '110478', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Clinical Study Report', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}, {'id': '110478', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Study Protocol', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}, {'id': '110478', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Informed Consent Form', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}, {'id': '110478', 'url': 'https://www.clinicalstudydatarequest.com', 'type': 'Individual Participant Data Set', 'comment': 'For additional information about this study please refer to the GSK Clinical Study Register'}], 'seeAlsoLinks': [{'url': 'https://www.clinicalstudydatarequest.com', 'label': 'Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.'}]}, 'descriptionModule': {'briefSummary': 'The new formulation administered as a 4th consecutive dose will be compared to the current formulation of the vaccine in this partially double blind study.\n\nThe study will be double-blind with respect to the two DTPa-HBV-IPV/Hib groups. The study will be open with respect to the DTPa-HBV-IPV group.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '23 Months', 'minimumAge': '18 Months', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.\n* Subjects must have completed full three-dose primary vaccination course with DTPa-HBV-IPV/Hib or DTPa-HBV-IPV in the primary study DTPa-HBV-IPV-109 (study NCT00320463).\n* A male or female between, and including 18 and 23 months of age at the time of the booster vaccination.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the booster dose of study vaccine, or planned use during the study period.\n* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the booster dose.\n* Participation in another clinical study, between the primary study NCT00320463 and the present booster study, or at any time during the study, in which the subject has been or will be exposed to an investigational or a non-investigational product.\n* Previous booster vaccination against diphtheria, tetanus, pertussis, poliomyelitis and hepatitis B since the conclusion visit of study NCT00320463.\n* Previous booster vaccination against Haemophilus influenzae diseases in the DTPa-HBV-IPV/Hib groups, since the conclusion visit of study NCT00320463.\n* History of exposure to diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and/or Haemophilus influenzae disease since the conclusion visit of study NCT00320463.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on physical examination.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.\n* Acute disease at the time of enrolment.\n* Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.\n* Any of the following adverse events having occurred after previous administration of DTP vaccine:\n* Hypersensitivity reaction due to the vaccine.\n* Encephalopathy defined as an acute, severe central nervous system disorder of unknown etiology occurring within 7 days following previous vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours.\n* Any of the following adverse events having occurred after previous administration of DTP vaccine:\n* Temperature of \\>= 40.0 °C (axillary temperature), within 48 hours of vaccination.\n* Collapse or shock-like state within 48 hours of vaccination.\n* Persistent, inconsolable crying lasting \\>= 3 hours, occurring within 48 hours of vaccination.\n* Convulsions with or without fever, occurring within 3 days of vaccination'}, 'identificationModule': {'nctId': 'NCT00611559', 'briefTitle': 'Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children', 'organization': {'class': 'INDUSTRY', 'fullName': 'GlaxoSmithKline'}, 'officialTitle': "Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children", 'orgStudyIdInfo': {'id': '110478'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Infanrix hexa Preservative-Free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa', 'interventionNames': ['Biological: Infanrix™ hexa']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Infanrix hexa Preservative-Containing Formulation Group', 'description': 'Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa', 'interventionNames': ['Biological: Infanrix™ hexa']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Infanrix penta Preservative-Free Formulation Group', 'description': 'Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.', 'interventionNames': ['Biological: Infanrix™ penta']}], 'interventions': [{'name': 'Infanrix™ penta', 'type': 'BIOLOGICAL', 'otherNames': ['Pediarix'], 'description': 'Subjects received a booster dose', 'armGroupLabels': ['Infanrix penta Preservative-Free Formulation Group']}, {'name': 'Infanrix™ hexa', 'type': 'BIOLOGICAL', 'description': 'Subjects received a booster dose', 'armGroupLabels': ['Infanrix hexa Preservative-Containing Formulation Group', 'Infanrix hexa Preservative-Free Formulation Group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '183046', 'city': 'Murmansk', 'country': 'Russia', 'facility': 'GSK Investigational Site', 'geoPoint': {'lat': 68.96778, 'lon': 33.09922}}, {'zip': '614022', 'city': 'Perm', 'country': 'Russia', 'facility': 'GSK Investigational Site', 'geoPoint': {'lat': 58.01046, 'lon': 56.25017}}, {'zip': '167000', 'city': 'Syktyvkar', 'country': 'Russia', 'facility': 'GSK Investigational Site', 'geoPoint': {'lat': 61.66393, 'lon': 50.8163}}], 'overallOfficials': [{'name': 'GSK Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'GlaxoSmithKline'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'GlaxoSmithKline', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}